

CD4 clone ZM180

Mouse Monoclonal Antibody

Instructions for Use

Specification:

Recognizes a protein of 55kDa, identified as CD4. It is a membrane glycoprotein of T lymphocytes that interacts with major histocompatibility complex class II antigens and is also a receptor for the human immunodeficiency virus. This protein is expressed not only in T lymphocytes, but also in B cells, macrophages, and granulocytes. The protein functions to initiate or augment the early phase of T-cell activation, and may function as an important mediator of indirect neuronal damage in infectious and immune-mediated diseases of the central nervous system. The majority of peripheral T-cell lymphomas are derived from the T-helper/regulatory cell subset so that most mature T-cell neoplasms are CD4+/CD8-. Anti-CD4 is used in the immunohistochemical staining of lymphoproliferative disorders to evaluate tumors with CD4 aberrant expression.

Availability:

Catalog No.	Contents	Volume
ILM4820-C01	CD4	0,1 ml concentrate
ILM4820-C05	CD4	0,5 ml concentrate
ILM4820-C1	CD4	1,0 ml concentrate

Intended use: For Research Use Only

Reactivity: Human

Clone: ZM180

Species of origin: Mouse

Isotype: IgG2a / λ

Control Tissue: Tonsil

Staining: Membranous

Immunogen: Recombinant fragment (around aa 216-396) of human CD4 protein (exact sequence is proprietary)

Presentation: Purified antibody diluted in Tris-HCL buffer and contain stabilizing protein and <0,1% sodium azide.

Application and suggested dilutions:

Pre-treatment: Heat induced epitope retrieval in 10 mM citrate buffer, pH6.0, for 20 minutes or in Tris EDTA buffer pH9.0 for 15 minutes is required for IHC staining on formalin-fixed, paraffin embedded tissue sections.

- Immunohistochemical staining of formalin-fixed, paraffin embedded tissue section (dilution up to 1:100-1:200)

The optimal dilution for a specific application should be determined by the investigator.

Storage & Stability: Store at 2-8 °C. Do not use after expiration date printed on the vial.

Reference:

- 1) Garcia-Herrera A, et al. Primary cutaneous small/medium CD4+ T-cell lymphomas: a heterogeneous group of tumors with different clinicopathologic feature and outcome. J Clin Oncol. 2008; 26:3364-71.
- 2) Akiyama T, et al. Pathol int. 2008 ; 56 :626-34